Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07271186 | Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease | PHASE2 | RECRUITING | 270 | — | — | Jan 9, 2026 | Apr 7, 2028 | May 20, 2026 | 51 | United States |
| Arm | Type | Description |
|---|---|---|
| ALN-ANG3 + evinacumab placebo | EXPERIMENTAL | - |
| ALN-ANG3 + evinacumab | EXPERIMENTAL | - |
| ALN-ANG3 placebo + evinacumab placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALN-ANG3 | DRUG | Administered per the protocol |
| Evinacumab | DRUG | Administered per the protocol |
| ALN-ANG3 placebo | DRUG | Administered per the protocol |
| Evinacumab placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management 2. Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening 3. eGFR 30 to 90 mL/min/1.73 m\^2 using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated...